华大集团CEO尹烨接受《环球时报》专访：世界将在一两代人内实现“百岁健康”

Core Insights - The article emphasizes the growing importance of biomanufacturing in China's economic development, highlighting its recognition alongside quantum technology and embodied intelligence as a key future industry [1] - The shift from a generics-based pharmaceutical industry to one focused on innovative drugs has garnered significant global attention [1] Industry Position - Biomanufacturing is positioned as a miraculous field with transformative potential, exemplified by companies like He Yuan Biotechnology, which utilizes rice to produce human serum albumin, addressing China's reliance on imports [2] - Gene editing technologies are revolutionizing the treatment of infectious and genetic diseases, showcasing the power of biomanufacturing to alter production and lifestyle [2] Health and Longevity - China's average life expectancy is projected to reach 79 years by 2024, necessitating a focus on preventing diseases to improve quality of life and reduce economic burdens [3] - The medical community is shifting towards a health-centered approach, emphasizing the need to manage diseases like Alzheimer's to extend life expectancy further [3] Technological Advancements - The potential for nationwide genetic testing could significantly enhance disease prevention, particularly for age-related conditions, by making screenings more affordable and accessible [4][5] - The U.S. acknowledges China's rapid rise in biotechnology, with both countries being leaders in the field, particularly in terms of application and industrial transformation [6] Competitive Landscape - The article discusses the comparable capabilities of China and the U.S. in biomanufacturing, noting that both utilize similar foundational tools, which allows for competitive parity [7] - China's biopharmaceutical sector is characterized by a strong engineering workforce and a culture of resilience in competition, contributing to its rapid advancements [7] Global Market Opportunities - Despite potential challenges from U.S. policies, China is encouraged to explore markets in developing regions, emphasizing the importance of technology accessibility for broader populations [8] - The trend of Chinese pharmaceutical companies engaging in international business development and licensing is expected to double, indicating a robust global strategy [9] Future Directions - Significant advancements are anticipated in four key areas: biomedicine and high-end medical devices, agricultural biotechnology, bioplastics, and marine biomanufacturing [10] - The agricultural sector is expected to benefit from improved breeding technologies and sustainable practices, while marine resources are seen as a new frontier for biomanufacturing [10]